FocalTherics (NASDAQ:FOCL) Receives Average Rating of “Hold” from Brokerages

FocalTherics (NASDAQ:FOCL) has been assigned a consensus rating of “Hold” from the five research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $9.00.

FOCL has been the topic of several analyst reports. Mizuho set a $15.00 price objective on FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. Piper Sandler reissued a “neutral” rating on shares of FocalTherics in a report on Friday. Wall Street Zen raised FocalTherics to a “hold” rating in a report on Saturday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd.

FocalTherics Price Performance

FOCL stock traded up $0.01 during trading on Friday, hitting $4.64. 1,495 shares of the stock traded hands, compared to its average volume of 62,962. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The stock has a market capitalization of $173.91 million, a PE ratio of -5.73 and a beta of -0.04. FocalTherics has a 1 year low of $1.30 and a 1 year high of $6.40. The stock has a 50 day simple moving average of $5.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FOCL. SmartHarvest Portfolios LLC bought a new stake in FocalTherics in the 1st quarter worth approximately $38,000. Lido Advisors LLC purchased a new position in shares of FocalTherics in the 1st quarter worth $40,000. Kovack Advisors Inc. bought a new stake in shares of FocalTherics in the fourth quarter worth $53,000. Rock Springs Capital Management LP increased its position in FocalTherics by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after acquiring an additional 16,500 shares during the last quarter. Finally, Leonteq Securities AG purchased a new stake in FocalTherics during the fourth quarter valued at $313,000. Institutional investors own 62.74% of the company’s stock.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.